An observational study in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Among 107 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 25 under way, 7 of them phase 3. Multiple Sclerosis · Novartis.
Among the 107 studies in Multiple Sclerosis by Novartis, this one is the 2nd largest by planned enrollment of the 41 observational ones that give a count, is one of 4 that started in 2026, is one of 41 observational ones, reaches primary completion later than 8 of the 24 other live ones, and was the 106th registered.
3,267 studies on the registry are indexed under Multiple Sclerosis; 662 are open to participants now.
Browse Multiple Sclerosis studies →9 of the 107 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 33 more countries
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 16 more countries
Ages 40–70
Novartis Pharmaceuticals · Sites in Greece
Ages 18–55
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18+ · Women only
By country, each count listing its studies:
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 24 · Phase 4 26
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 151 across the 65 interventional studies, 312 across the 41 observational. Of the 78 that completed or were terminated, 45 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,718 studies on the registry; 221 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 438 (75%) have results posted.
6 of the studies in Multiple Sclerosis by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06847724Phase 3SandozComparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis | 2026-11 |
| NCT07821411Novartis PharmaceuticalsA Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | 2026-11-30 |
| NCT05776888Novartis PharmaceuticalsEarly Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years | 2026-12-16 |
| NCT07779460Novartis PharmaceuticalsA Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | 2026-12-31 |
| NCT05809986Novartis PharmaceuticalsOfatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study | 2026-12-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 107 studies in Multiple Sclerosis by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the real-world persistence and adherence to ofatumumab (OMB) treatment in adult patients with relapsing multiple sclerosis (RMS). This is a non-interventional study using administrative claims data available in Germany and Japan.
Adult RMS patients who start new treatment with OMB or a DMT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients will be included in the OMB or disease modifying treatment (DMT) cohort if they meet the following criteria:
Exclusion criteria:
Patients will be excluded if they meet any of the following criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Adult patients diagnosed with RMS and newly treated with OMB.
A sub-group of the OMB Cohort. Patients with no record of treatment with a DMT before starting OMB treatment.
A sub-group of the OMB Cohort. Patients who used at least one DMT before starting OMB treatment.
Adult patients diagnosed with RMS who began new treatment with a DMT and had no record of treatment with OMB.
A sub-group of the DMT Cohort. Patients whose first DMT prescribed during the inclusion period is an LET.
A sub-group of the LET Cohort. Patients with no record of a DMT before staring an LET.
A sub-group of the LET Cohort. Patients who used at least one DMT before starting an LET.
A sub-group of the DMT Cohort. Patients whose first DMT prescribed during the inclusion period is an MET.
A sub-group of the MET Cohort. Patients with no record of a DMT before staring an MET.
A sub-group of the MET Cohort. Patients who used at least one DMT before starting an MET.
A sub-group of the DMT Cohort. Patients whose first DMT prescribed during the inclusion period is a HET.
A sub-group of the HET Cohort. Patients with no record of a DMT before starting a HET.
A sub-group of the HET Cohort. Patients who used at least one DMT before starting a HET.
Proportion of Patients Persistent With OMB
Persistence is defined as the absence of evidence of treatment switch or discontinuation at pre-defined timepoints of interest (6 months, 12 months follow-up).
Time frame: 6 months, 12 months
Proportion of Patients Adherent to OMB
Adherence measured using the proportion of days covered (PDC). PDC is defined as the number of days covered by the treatment divided by the period considered in the analysis, including overlaps between prescriptions.
Time frame: 6 months, 12 months
Number of Treatments Used
Time frame: Baseline, up to approximately 4 years
Number of Patients by Sequence of Treatments Used
Time frame: Baseline, up to approximately 4 years
Number of Patients by Line of Therapy (LOT)
Time frame: Baseline, up to approximately 4 years
Number of Patients by Type of Treatment
Time frame: Baseline, up to approximately 4 years
Duration of Treatment
Time frame: Baseline, up to approximately 4 years
Percentage of Patients Who Switch Treatment
Percentage of patients who switch from OMB treatment to another DMT.
Time frame: Up to approximately 4 years
Percentage of Patients Who Discontinue OMB Treatment
Time frame: Up to approximately 4 years
Number of Patients by Treatments Received After OMB Treatment
Time frame: Up to approximately 4 years
Baseline Demographics
Time frame: Baseline
Number of Patients by Index Year
Index year is the year of index date. Index date is the date of first claim for OMB or DMT.
Time frame: Baseline
Charlson Comorbidity Index (CCI) Score
CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases. It predicts the ten-year mortality for a patient who may have a range of comorbid conditions. CCI can be classified as low (0-1) and high (≥2).
Time frame: Baseline
Number of Patients per Top 10 Comorbidities Observed During the Baseline Period
Time frame: Baseline
Frequency of at least One All-cause and MS-specific Hospitalization During the Baseline Period
Time frame: Baseline
Number of Hospitalizations Per Person Year
RMS-specific and all-cause hospitalizations.
Time frame: Baseline
Number of Relapses Per Person Year
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.